Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Plasmacytoma 1Osteosarcoma 1Neuroblastoma 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Carcinoma, Basal Cell 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Ifosfamide 30Methotrexate 27Doxorubicin 25Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10cabozantinib 9apatinib 9Specimen Handling 9Carboplatin 9fludarabine 8X-Rays 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Radiotherapy 7Phantoms, Imaging 7Biopsy 7Topotecan 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Osteosarcoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡